急性間歇性紫質症市場規模、佔有率、成長分析（按診斷、按治療、按最終用戶、按地區）- 2025 年至 2032 年產業預測

急性間歇性紫質症市場規模預計在 2023 年達到 43.2 億美元，到 2032 年將達到 56.9 億美元，預計在預測期內（2025-2032 年）的複合年成長率為 3.1%。

由於人們認知的提高、診斷方法的進步以及創新治療方法的發展，急性間歇性紫質症(AIP) 市場正在經歷顯著成長。這種影響血紅素合成的罕見遺傳性疾病是醫療領域的一股驅動力。基因檢測等診斷能力的提高可以早期準確地識別 AIP 病例。此外，製藥業正專注於新治療方法的研究和開發，而改善病患教育有助於有效控制症狀。儘管取得了這些進展，但診斷不足和治療選擇有限等挑戰仍然存在。醫學專家、研究人員和製藥公司之間的合作方式對於應對 AIP 市場的複雜性和改善患者的治療效果至關重要。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管分析

急性間歇性紫質症市場規模（依診斷及複合年成長率）（2025-2032）

• 市場概覽
• 血液檢查
• 尿液檢查
• DNA檢測
• 血清檢測

急性間歇性紫質症市場規模（依治療類型和複合年成長率） (2025-2032)

• 市場概覽
• 促性腺激素分泌釋放激素類似物
• 預防性注射血紅素

急性間歇性紫質症市場規模（依最終用戶分類）及複合年成長率（2025-2032）

• 市場概覽
• 醫院
• 診所
• 研究中心

急性間歇性紫質症市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

    主要企業簡介

    • Alnylam Pharmaceuticals（美國）
    • Recordati SpA（義大利）
    • 賽諾菲公司（法國）
    • BioMarin製藥公司（美國）
    • 西門子醫療股份公司（德國）
    • F. Hoffmann-La Roche Ltd（瑞士）
    • 武田藥品工業株式會社（日本）
    • 益普生製藥（法國）
    • Clinuvel Pharmaceuticals Ltd（澳洲）
    • Quest Diagnostics（美國）
    • 梅奧診所實驗室（美國）
    • Bachem Holding AG（瑞士）
    • Grifols, SA（西班牙）
    • 輝凌製藥（瑞士）
    • 太陽製藥工業有限公司（印度）
    • Moderna公司（美國）
    • Dicerna Pharmaceuticals, Inc.（美國）
    • Zambon SpA（義大利）
    • Luitpold Pharmaceuticals, Inc.（美國）
    • Vifor Pharma（瑞士）

結論和建議

Acute Intermittent Porphyria Market size was valued at USD 4.32 billion in 2023 and is poised to grow from USD 4.45 billion in 2024 to USD 5.69 billion by 2032, growing at a CAGR of 3.1% during the forecast period (2025-2032).

The Acute Intermittent Porphyria (AIP) market is experiencing significant growth due to increased awareness, advancements in diagnostics, and the development of innovative treatment options. This rare genetic disorder, which affects heme synthesis, is gaining traction in the healthcare sector. Enhanced diagnostic capabilities, such as genetic testing, have led to earlier and more accurate identification of AIP cases. Furthermore, the pharmaceutical industry is focusing on research and development of novel therapies, while improved patient education is helping to manage symptoms effectively. Despite these advancements, challenges such as underdiagnosis and limited treatment options persist. A collaborative approach among healthcare professionals, researchers, and pharmaceutical companies is essential to navigate the complexities of the AIP market and improve patient outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Acute Intermittent Porphyria market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Acute Intermittent Porphyria Market Segments Analysis

Global Acute Intermittent Porphyria Market is segmented by Diagnosis, Treatment, End Users and region. Based on Diagnosis, the market is segmented into Blood Test, Urine Test, DNA Test and Serum Test. Based on Treatment, the market is segmented into Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions. Based on End Users, the market is segmented into Hospitals, Clinics and Research Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Acute Intermittent Porphyria Market

The increasing emphasis on advanced diagnostic techniques has significantly improved the identification of Acute Intermittent Porphyria (AIP) cases, enabling quicker intervention and more effective management. Furthermore, the development of innovative treatment options, including hematin infusions and novel RNA interference therapies such as givosiran, presents robust strategies for managing acute attacks and providing sustained symptom control. This combination of enhanced detection and evolving therapeutic alternatives is driving the growth of the AIP market, ultimately improving patient outcomes and quality of life for those affected by this rare genetic disorder.

Restraints in the Acute Intermittent Porphyria Market

A significant constraint in the Acute Intermittent Porphyria (AIP) market is the challenge of underdiagnosis, which stems from the condition's rarity and the intricate nature of its symptoms. This complexity often results in delays or even oversight in recognizing those affected by AIP. Furthermore, the limited availability of treatment options compounds this issue, as current therapies primarily focus on managing symptoms rather than providing a definitive cure. This scenario effectively hampers the market's growth potential, as both diagnosis and treatment face considerable hurdles that can impede timely and effective patient care.

Market Trends of the Acute Intermittent Porphyria Market

The Acute Intermittent Porphyria (AIP) market is experiencing significant growth, driven by advancements in genetic testing technologies that enhance the accuracy and timeliness of diagnoses. This trend is complemented by the emergence of innovative treatments such as RNA interference (RNAi) therapies, notably givosiran, which offer a targeted approach to address the genetic underpinnings of AIP. As these testing methodologies and cutting-edge treatments gain traction, they are likely to improve patient outcomes and foster more personalized management strategies. This convergence of diagnostics and therapeutics is expected to propel market expansion and stimulate interest from pharmaceutical companies and investors alike.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis

Global Acute Intermittent Porphyria Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Blood Test
• Urine Test
• DNA Test
• Serum Test

Global Acute Intermittent Porphyria Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Gonadotropin-Releasing Hormone Analogues
• Prophylactic Hematin Infusions

Global Acute Intermittent Porphyria Market Size by End Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Research Centers

Global Acute Intermittent Porphyria Market Size & CAGR (2025-2032)

• North America (Diagnosis, Treatment, End Users)
  • US
  • Canada
• Europe (Diagnosis, Treatment, End Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Treatment, End Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Treatment, End Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Treatment, End Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Alnylam Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recordati S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clinuvel Pharmaceuticals Ltd (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayo Clinic Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bachem Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dicerna Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zambon S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Luitpold Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vifor Pharma (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations